Clinical Trials Logo
  1. Home
  2. Glioma, Malignant
  3. NCT04904419
  4. Details
NCT04904419 Clinical Trial

Multi-center Research Project for Glioma Molecular Pathology Intraoperative Rapid Detection

Glioma, Malignant Clinical Trial

Official title:
Multi-center Research Project for Glioma Molecular Pathology Intraoperative Rapid Detection

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT04904419
Other study ID # KY2020-1298
Secondary ID
Status Completed
Phase
First received
Last updated
Start date August 1, 2021
Est. completion date January 31, 2022

Study information
Verified date April 2023
Source Huashan Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

We explores the accuracy and sensitivity of rapid intraoperative detection of IDH, TERT, BRAF indicators through a prospective clinical multi-center study. This part includes a total of 300 fresh tissue samples, paired blood samples, relevant clinical information and follow-up information from 300 patients with different grades of adult glioma. By comparing with the postoperative sequencing results, the specificity and sensitivity of intraoperative IDH and TERT rapid detection results are clear.

Recruitment information / eligibility
Status Completed
Enrollment 137
Est. completion date January 31, 2022
Est. primary completion date January 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - 1. Glioma patients with Informed Consent Form 2. Glioma patients with intact clinical information Exclusion Criteria: - 1. Glioma patients without Informed Consent Form 2. Glioma patients without intact clinical information

Study Design

Related Conditions & MeSH terms

Intervention

Diagnostic Test:
• Intraoperative Rapid Detection mutation of IDH, TERT and BRAF v600e
Intraoperative Rapid Detection mutation of IDH, TERT and BRAF v600e

Locations
Country Name City State
China The First Affiliated Hospital of Fujian Medical University Fuzhou
China Huashan Hospital Shanghai
China Huashan Hospital(West campus) Shanghai
China General Hospital of Ningxia Medical University Yinchuan

Sponsors (1)
Lead Sponsor Collaborator
Jinsong Wu

Country where clinical trial is conducted

China, 

Outcome
Type Measure Description Time frame Safety issue
Primary Intraoperative Rapid Detection mutation of IDH, TERT and BRAF v600e Intraoperative Rapid Detection mutation of IDH, TERT and BRAF v600e
See also
  Status Clinical Trial Phase
Recruiting NCT05557240 - Neoantigens Phase I Trial in Newly Diagnosed Glioblastoma Patients N/A
Recruiting NCT05485038 - General Anesthesia Versus Awake Surgery in Resection of Gliomas and Metastases of Motor Areas N/A
Recruiting NCT05474573 - Concurrent Fluorescence and Sonographically Guided Eradication of Contrast-enhancing Gliomas and Metastases N/A
Active, not recruiting NCT04547621 - HSRT and IMRT Chemoradiotherapy for Newly Diagnosed GBM Phase 1/Phase 2
Recruiting NCT05076513 - Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma Early Phase 1
Completed NCT05806619 - Glioma: Biomolecular Aspects
Not yet recruiting NCT04562077 - Role of Surgery in Treatment of Recurrent Brian Glioma:Prognostic Factors and Outcome
Recruiting NCT06038760 - Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO)
Completed NCT04497142 - Effect of Perampanel on Peritumoral Hyperexcitability in HGG Phase 1/Phase 2
Recruiting NCT05500508 - Oral AMXT 1501 Dicaprate in Combination With IV DFMO Phase 1/Phase 2
Active, not recruiting NCT05656053 - Intraoperative Rapid Diagnosis of Glioma Based on Fusion of Magnetic Resonance and Ultrasound Imaging
Recruiting NCT06196918 - Efficacy and Safety of Rivaroxaban in the Prevention of Venous Thromboembolism in Glioma Patients N/A
Recruiting NCT05556486 - Mapping of Tumor Stem Cells in the Resection Marigin During Extirpation of Highly Malignant Gliomas Using GlioStem
Recruiting NCT05406700 - Niraparib In Recurrent IDH 1/2 Gliomas Early Phase 1
Recruiting NCT05773326 - Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG Early Phase 1
Active, not recruiting NCT05063682 - The Efficacy and Safety of Brain-targeting Immune Cells (EGFRvIII-CAR T Cells) in Treating Patients With Leptomeningeal Disease From Glioblastoma. Administering Patients EGFRvIII -CAR T Cells May Help to Recognize and Destroy Brain Tumor Cells in Patients Phase 1
Completed NCT05100173 - Clinical Evaluation of Genetron IDH1 PCR Kit in Glioma Patients
Completed NCT05100602 - Clinical Evaluation of Genetron TERT PCR Kit in Glioma Patients
Recruiting NCT05182905 - AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients Early Phase 1
Recruiting NCT06381726 - Personalized Rendering of Motor System Functional Plasticity Potential to Improve Glioma Resection and Quality of Life N/A